https://hotcopper.com.au/threads/an...olders.3869075/?post_id=29169848#.Wk1uo00Uln0
From letter to shareholders:
The following points highlight our current position of strength:
We have a strong financial position with $26 million in cash and
a further $6 million soon anticipated from the R&D tax incentive
programme
Our cash resources can fund our planned clinical activities into
2019, including new studies in Head & Neck cancer, Colorectal
cancer and Uveal melanoma
This makes me hope it is a great deal!
Good luck all
